BAP1 loss in ccRCC defines an aggressive, HRD-like subset, in which early clinical data with the PARP inhibitor olaparib have shown signals of activity, including tumor shrinkage and durable disease control in patients with BAP1/DDR alterations. This evidence concerns the gene PARP1 and neoplasm.